Lantheus Holdings (LNTH) Research & Development (2014 - 2026)
Lantheus Holdings (LNTH) posted quarterly Research & Development of $39.4 million for Q1 2026, down 7.35% year-over-year from $42.5 million in Q1 2025, and up 132.5% quarter-over-quarter from -$121.2 million in Q4 2025.
Lantheus Holdings (LNTH) Research & Development (2014 - 2026) Analysis & Trends
Lantheus Holdings (LNTH) has reported Research & Development for 13 consecutive years, with $39.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development fell 7.35% year-over-year to $39.4 million; the TTM figure through Mar 2026 stood at $7.3 million (down 97.15% YoY), while the FY2025 annual figure was $11.2 million, down 93.34% from the prior year.
- Research & Development improved to $39.4 million in Q1 2026 per LNTH's latest filing, from -$121.2 million in the prior quarter.
- Across five years, Research & Development topped out at $220.5 million in Q4 2022 and bottomed at -$121.2 million in Q4 2025.
- Historically, Research & Development has averaged $43.0 million across 5 years, with a median of $37.4 million in 2023.
- Annual changes were most pronounced in 2022 — Research & Development surged 5568.51% — and 2025, when it slumped 191.73%.
- Lantheus Holdings' Research & Development stood at $220.5 million in 2022, then sank by 63.34% to $80.9 million in 2023, then jumped by 63.38% to $132.1 million in 2024, then plunged by 191.73% to -$121.2 million in 2025, then jumped by 132.5% to $39.4 million in 2026.
- Business Quant data shows LNTH's Research & Development at $39.4 million in Q1 2026, -$121.2 million in Q4 2025, and $48.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 970.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -1.05 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 146.30 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 248.30 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 326.70 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 92.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Lantheus Holdings | 6.54 Bn | 5.94 Bn | 241.86 Mn | 82.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 82.81 Mn |
| Mar 31, 2026 | 39.38 Mn |
| Dec 31, 2025 | -121.17 Mn |
| Sep 30, 2025 | 48.03 Mn |
| Jun 30, 2025 | 41.04 Mn |
| Mar 31, 2025 | 42.50 Mn |
| Dec 31, 2024 | 132.10 Mn |
| Sep 30, 2024 | 36.00 Mn |
| Jun 30, 2024 | 45.04 Mn |
| Mar 31, 2024 | 28.00 Mn |
| Dec 31, 2023 | 80.85 Mn |
| Sep 30, 2023 | 37.40 Mn |
| Jun 30, 2023 | 15.90 Mn |
| Mar 31, 2023 | 32.62 Mn |
| Dec 31, 2022 | 220.55 Mn |
| Sep 30, 2022 | 25.41 Mn |
| Jun 30, 2022 | 14.74 Mn |
| Mar 31, 2022 | 12.20 Mn |
| Dec 31, 2021 | -4.03 Mn |
| Sep 30, 2021 | 11.25 Mn |